Search

Displaying results 5241 - 5250 of 10000 in total
  1. Drug

    Apadenoson

    go.drugbank.com/drugs/DB05009
    Investigational

    It is developed by Bristol-Myers Squibb and is in phase II of clinical trials. … Apadenoson is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies.

  2. Drug

    Bevantolol

    go.drugbank.com/drugs/DB01295
    Investigational

    Mechanism of Action Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors.

  3. Drug

    EW-A-401

    go.drugbank.com/drugs/DB05525
    Investigational

    This specific transcription factor has been shown in animal studies to increase expression of the VEGF-A gene, and to promote the growth of new blood vessels. … EW-A-401 is a circle of genetic material (plasmid DNA) that instructs the body to produce a genetically-engineered transcription factor, a protein that regulates expression of genes.

    Synonyms: EW-A-401 DNA Plasmid Vector
  4. Drug

    Melperone

    go.drugbank.com/drugs/DB09224
    Investigational

    It has been well established in the treatment of confusion, anxiety, restlessness (particularly in the elderly) and schizophrenia as It is known to be well-tolerated with an excellent safety profile. … Melperone has been used for a span of greater than 30 years in the European Union [L1316].

  5. Drug

    Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10801
    ApprovedInvestigational

    diphtheriae* grown in another culture. … Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria

  6. Drug

    MIP-1095 I-131

    go.drugbank.com/drugs/DB14978
    Investigational

    MIP-1095 I-131 is under investigation in clinical trial NCT03030885 (Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)).

  7. Drug

    MIV-701

    go.drugbank.com/drugs/DB05736
    Experimental

    MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.

  8. Drug

    P-nitrobiphenyl

    go.drugbank.com/drugs/DB12300
    ApprovedWithdrawn

    Pnb has been used in trials studying the treatment of Pelvic Organ Prolapse.

  9. Drug

    Bunamiodyl

    go.drugbank.com/drugs/DB04814
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.

  10. Drug

    Dantron

    go.drugbank.com/drugs/DB04816
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.